ith irinotecan and temozolomide in neuroblastoma. J Clin Oncol. 2010, 28 abstr 10593. 41. Huck JJ, Zhang M, Hyper ML, Manfredi MG. Anti tumor activity of the aurora A inhibitor MLN8237 in diffuse large B cell lymphoma preclinical model. Blood . 2008, 112 abstr 1592. 42. Zhang M, Huck J, AT9283 Sells T, et al. In vivo characterization of the aurora A kinase inhibitor MLN8237 in subcutaneous and disseminated models of human cancer. Proc Am Assoc Cancer Res. 2008, 49 abstr 5646. 43. Nawrocki ST, Medina E, Smith S, et al. The aurora kinase inhibitor MLN8237 has potent anticancer activity in CML and Ph+ ALL models and significantly increases the efficacy of nilotinib. Blood . 2008, 112 abstr 3198. 44. Gorgun G, Calabrese E, Hideshima T, et al. A novel aurora A kinase inhibitor MLN 8237 induces cytotoxicity and cell cycle arrest in multiple myeloma.
Blood. 2010, 115:5202 13. 45. Kelly KR, Swords RT, Mahalingam D, et al. The novel orally active aurora A kinase inhibitor MLN8237 is highly active in preclinical models of acute myeloid leukemia and significantly increases the efficacy of cytarabine. Blood . 2009, 114 abstr 2087. 46. Huck J, Zhang M, Hyer M, et al. Antitumor activity of the aurora A inhibitor NVP-TAE684 MLN8237 in combination with docetaxel in xenograft models of breast and prostate cancer. Proc Am Assoc Cancer Res. 2009, 50 abstr 3724. 47. Infante J, Dees EC, Cohen RB, et al. Phase I study of the safety, pharmacokinetics , and pharmacodynamics of MLN8237, a selective aurora A kinase inhibitor, in the United States. Eur J Cancer Suppl. 2008, 6:90. abstr 280. 48.
Cervantes Ruiperez A, Elez ME, Rosello S, et al. Phase I pharmacokinetic and pharmacodynamic study of MLN8237, a novel selective aurora A kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2009, 27 abstr 2565. 49. Dees EC, Infante JR, Burris HA, et al. Phase I study of the investigational drug MLN8237, an aurora A kinase inhibitor, in patients with solid tumors. J Clin Oncol. 2010, 28 abstr 3010. 50. Cervantes Ruiperez, Burris HA, Cohen RB, et al. Pharmacokinetic and pharmacodynamic results from two phase I studies of the investigational selective aurora A kinase inhibitor MLN8237: Exposure dependent AAK inhibition in human tumors. J Clin Oncol. 2010, 28 abstr 3031. 51. Mosse YP, Lipsitz EG, Maris JM, et al.
A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora A kinase: A Children,s Oncology Group Phase I Consortium study. J Clin Oncol. 2010, 28 abstr 9529. Green et al. Page 16 Expert Opin Drug Discov. Author manuscript, available in PMC 2012 March 1. NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript 52. Shah NP, Kasap C, Paquette R, et al. Targeting drug resistant CML and Ph+ ALL with the spectrum selective protein kinase inhibitor XL 228. Blood . 2007, 110 abstr 474. 53. Cortes J, Paquette R, Talpaz M, et al. Preliminary clinical activity in a phase I trial of the BCRAbl/ IGF 1R/aurora kinase inhibitor XL 228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutations. Blood . 2008, 112 abstr 3232. 54. Smith DC, Britten C, Garon EB, et al.
A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients with solid tumors or multiple myeloma. J Clin Oncol. 2010, 28 abstr 3105. 55. Shiotsu Y, Kiyoi H, Ozeki K, et al. KW 2449, a novel multi kinase inhibitor against FLT33, Abl, FGFR1 and aurora, suppresses the growth of AML both in vitro and in vivo. Blood . 2007, 110 abstr 1832. 56. Cortes J, Roboz GJ, Kantarjian HM, et al. A phase I dose escalation study of KW 2449, an oral multi kinase inhibitor against FLT3, Abl, FGFR1 and aurora in patients with relapsed/refractory AML, ALL and MDS or resistant/intolerant CML. Blood . 2008, 112 abstr 2967. 57. Gurtler U, Tontsch Grunt U, Jarvis M, et al. Effect of BI 811283, a novel inhibitor of aurora B kinase, on tumor senescence and apoptosis. J Clin Oncol. 2010, 28 abstr e13